ImmuCell Corporation (ICCC)
USD 5.29
(-1.22%)
USD 5.29
(-1.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.39 Million USD | -42.52% |
| 2022 | 7.64 Million USD | -11.63% |
| 2021 | 8.65 Million USD | 26.13% |
| 2020 | 6.86 Million USD | 1.82% |
| 2019 | 6.74 Million USD | 29.77% |
| 2018 | 5.19 Million USD | -0.52% |
| 2017 | 5.22 Million USD | -3.68% |
| 2016 | 5.42 Million USD | -13.28% |
| 2015 | 6.25 Million USD | 40.5% |
| 2014 | 4.44 Million USD | 45.36% |
| 2013 | 3.06 Million USD | 0.21% |
| 2012 | 3.05 Million USD | 8.55% |
| 2011 | 2.81 Million USD | 22.21% |
| 2010 | 2.3 Million USD | -4.1% |
| 2009 | 2.4 Million USD | 15.73% |
| 2008 | 2.07 Million USD | -45.41% |
| 2007 | 3.8 Million USD | 30.2% |
| 2006 | 2.91 Million USD | -12.85% |
| 2005 | 3.34 Million USD | 49.04% |
| 2004 | 2.24 Million USD | 11.8% |
| 2003 | 2.01 Million USD | -40.62% |
| 2002 | 3.38 Million USD | -2.22% |
| 2001 | 3.46 Million USD | 16.65% |
| 2000 | 2.96 Million USD | 3.85% |
| 1999 | 2.85 Million USD | 9.92% |
| 1998 | 2.6 Million USD | -10.34% |
| 1997 | 2.9 Million USD | 11.54% |
| 1996 | 2.6 Million USD | -16.13% |
| 1995 | 3.1 Million USD | 19.23% |
| 1994 | 2.6 Million USD | 18.18% |
| 1993 | 2.2 Million USD | 29.41% |
| 1992 | 1.7 Million USD | 88.89% |
| 1991 | 900 Thousand USD | -52.63% |
| 1990 | 1.9 Million USD | 46.15% |
| 1989 | 1.3 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.29 Million USD | 82.46% |
| 2024 Q2 | 1.23 Million USD | -46.39% |
| 2023 Q3 | 1.26 Million USD | 21.36% |
| 2023 FY | 3.86 Million USD | -49.41% |
| 2023 Q2 | 1.04 Million USD | 247.07% |
| 2023 Q1 | 300.77 Thousand USD | -69.69% |
| 2023 Q4 | 1.25 Million USD | -0.7% |
| 2022 FY | 7.64 Million USD | -11.63% |
| 2022 Q4 | 992.39 Thousand USD | -46.24% |
| 2022 Q1 | 3.1 Million USD | 21.18% |
| 2022 Q2 | 1.7 Million USD | -44.98% |
| 2022 Q3 | 1.84 Million USD | 8.12% |
| 2021 Q4 | 2.56 Million USD | 5.87% |
| 2021 Q3 | 2.41 Million USD | 16.6% |
| 2021 Q2 | 2.07 Million USD | 29.47% |
| 2021 FY | 8.65 Million USD | 26.13% |
| 2021 Q1 | 1.6 Million USD | -1.16% |
| 2020 Q2 | 1.28 Million USD | -42.61% |
| 2020 Q4 | 1.62 Million USD | -5.89% |
| 2020 FY | 6.86 Million USD | 1.82% |
| 2020 Q3 | 1.72 Million USD | 34.23% |
| 2020 Q1 | 2.23 Million USD | 21.66% |
| 2019 Q1 | 2.2 Million USD | 57.7% |
| 2019 FY | 6.74 Million USD | 29.77% |
| 2019 Q2 | 1.24 Million USD | -43.27% |
| 2019 Q3 | 1.45 Million USD | 16.2% |
| 2019 Q4 | 1.83 Million USD | 26.64% |
| 2018 Q4 | 1.39 Million USD | 46.8% |
| 2018 Q3 | 950.96 Thousand USD | -36.04% |
| 2018 Q2 | 1.48 Million USD | 9.35% |
| 2018 Q1 | 1.35 Million USD | 12.19% |
| 2018 FY | 5.19 Million USD | -0.52% |
| 2017 Q1 | 2.15 Million USD | 76.58% |
| 2017 FY | 5.22 Million USD | -3.68% |
| 2017 Q4 | 1.21 Million USD | 29.51% |
| 2017 Q3 | 935.85 Thousand USD | 1.57% |
| 2017 Q2 | 921.35 Thousand USD | -57.18% |
| 2016 Q1 | 1.75 Million USD | 6.04% |
| 2016 FY | 5.42 Million USD | -13.28% |
| 2016 Q4 | 1.21 Million USD | 1.16% |
| 2016 Q3 | 1.2 Million USD | -2.84% |
| 2016 Q2 | 1.23 Million USD | -29.46% |
| 2015 Q4 | 1.65 Million USD | 2.83% |
| 2015 FY | 6.25 Million USD | 40.5% |
| 2015 Q1 | 1.85 Million USD | 37.85% |
| 2015 Q3 | 1.61 Million USD | 42.57% |
| 2015 Q2 | 1.13 Million USD | -38.92% |
| 2014 Q2 | 878.52 Thousand USD | -23.6% |
| 2014 FY | 4.44 Million USD | 45.36% |
| 2014 Q4 | 1.34 Million USD | 24.57% |
| 2014 Q3 | 1.07 Million USD | 22.69% |
| 2014 Q1 | 1.14 Million USD | 89.24% |
| 2013 Q4 | 607.64 Thousand USD | -1.31% |
| 2013 Q1 | 1.05 Million USD | 40.44% |
| 2013 Q2 | 783.67 Thousand USD | -25.62% |
| 2013 FY | 3.06 Million USD | 0.21% |
| 2013 Q3 | 615.71 Thousand USD | -21.43% |
| 2012 FY | 3.05 Million USD | 8.55% |
| 2012 Q4 | 750.21 Thousand USD | 20.82% |
| 2012 Q3 | 620.95 Thousand USD | -7.39% |
| 2012 Q2 | 670.51 Thousand USD | -33.78% |
| 2012 Q1 | 1.01 Million USD | 39.66% |
| 2011 Q2 | 694.52 Thousand USD | -20.01% |
| 2011 Q1 | 868.23 Thousand USD | 48.4% |
| 2011 Q3 | 526.03 Thousand USD | -24.26% |
| 2011 Q4 | 725.01 Thousand USD | 37.83% |
| 2011 FY | 2.81 Million USD | 22.21% |
| 2010 FY | 2.3 Million USD | -4.1% |
| 2010 Q1 | 739.59 Thousand USD | 25.1% |
| 2010 Q2 | 620.15 Thousand USD | -16.15% |
| 2010 Q3 | 357.26 Thousand USD | -42.39% |
| 2010 Q4 | 585.04 Thousand USD | 63.76% |
| 2009 Q2 | 488.54 Thousand USD | -32.31% |
| 2009 Q1 | 721.76 Thousand USD | 26.49% |
| 2009 Q4 | 591.19 Thousand USD | -1.38% |
| 2009 FY | 2.4 Million USD | 15.73% |
| 2009 Q3 | 599.46 Thousand USD | 22.7% |
| 2008 Q3 | 302.63 Thousand USD | -20.26% |
| 2008 Q4 | 570.63 Thousand USD | 88.55% |
| 2008 FY | 2.07 Million USD | -45.41% |
| 2008 Q1 | 821.82 Thousand USD | -3.53% |
| 2008 Q2 | 379.54 Thousand USD | -53.82% |
| 2007 Q1 | 1.04 Million USD | 48.94% |
| 2007 Q2 | 448.24 Thousand USD | -57.1% |
| 2007 Q4 | 851.86 Thousand USD | -41.47% |
| 2007 Q3 | 1.45 Million USD | 224.68% |
| 2007 FY | 3.8 Million USD | 30.2% |
| 2006 Q2 | 455.61 Thousand USD | -55.98% |
| 2006 Q4 | 701.58 Thousand USD | -3.46% |
| 2006 Q3 | 726.71 Thousand USD | 59.5% |
| 2006 Q1 | 1.03 Million USD | 13.48% |
| 2006 FY | 2.91 Million USD | -12.85% |
| 2005 Q3 | 767.68 Thousand USD | 20.93% |
| 2005 Q4 | 912.08 Thousand USD | 18.81% |
| 2005 Q2 | 634.79 Thousand USD | -38.65% |
| 2005 FY | 3.34 Million USD | 49.04% |
| 2005 Q1 | 1.03 Million USD | 73.32% |
| 2004 FY | 2.24 Million USD | 11.8% |
| 2004 Q1 | 782.09 Thousand USD | 49.9% |
| 2004 Q2 | 365.7 Thousand USD | -53.24% |
| 2004 Q3 | 502.51 Thousand USD | 37.41% |
| 2004 Q4 | 596.94 Thousand USD | 18.79% |
| 2003 Q2 | 332.26 Thousand USD | -45.63% |
| 2003 FY | 2.01 Million USD | -40.62% |
| 2003 Q4 | 521.74 Thousand USD | 15.13% |
| 2003 Q3 | 453.16 Thousand USD | 36.39% |
| 2003 Q1 | 611.13 Thousand USD | -34.77% |
| 2002 FY | 3.38 Million USD | -2.22% |
| 2002 Q4 | 936.9 Thousand USD | 33.94% |
| 2002 Q3 | 699.5 Thousand USD | -2.02% |
| 2002 Q2 | 713.9 Thousand USD | -31.02% |
| 2002 Q1 | 1.03 Million USD | -19.15% |
| 2001 Q3 | 565.86 Thousand USD | -32.45% |
| 2001 Q4 | 1.28 Million USD | 126.22% |
| 2001 Q2 | 837.73 Thousand USD | 3.13% |
| 2001 Q1 | 812.3 Thousand USD | -10.43% |
| 2001 FY | 3.46 Million USD | 16.65% |
| 2000 FY | 2.96 Million USD | 3.85% |
| 2000 Q4 | 906.89 Thousand USD | 68.14% |
| 2000 Q3 | 539.35 Thousand USD | -26.47% |
| 2000 Q2 | 733.55 Thousand USD | -6.9% |
| 2000 Q1 | 787.94 Thousand USD | 3.98% |
| 1999 FY | 2.85 Million USD | 9.92% |
| 1999 Q3 | 700 Thousand USD | 16.67% |
| 1999 Q4 | 757.82 Thousand USD | 8.26% |
| 1999 Q1 | 800 Thousand USD | 14.29% |
| 1999 Q2 | 600 Thousand USD | -25.0% |
| 1998 Q1 | 700 Thousand USD | -36.36% |
| 1998 FY | 2.6 Million USD | -10.34% |
| 1998 Q4 | 700 Thousand USD | 16.67% |
| 1998 Q3 | 600 Thousand USD | 0.0% |
| 1998 Q2 | 600 Thousand USD | -14.29% |
| 1997 Q3 | 600 Thousand USD | 50.0% |
| 1997 Q4 | 1.1 Million USD | 83.33% |
| 1997 FY | 2.9 Million USD | 11.54% |
| 1997 Q1 | 800 Thousand USD | -11.11% |
| 1997 Q2 | 400 Thousand USD | -50.0% |
| 1996 FY | 2.6 Million USD | -16.13% |
| 1996 Q4 | 900 Thousand USD | 80.0% |
| 1996 Q3 | 500 Thousand USD | 25.0% |
| 1996 Q2 | 400 Thousand USD | -55.56% |
| 1996 Q1 | 900 Thousand USD | 28.57% |
| 1995 FY | 3.1 Million USD | 19.23% |
| 1995 Q4 | 700 Thousand USD | 0.0% |
| 1995 Q3 | 700 Thousand USD | -12.5% |
| 1995 Q2 | 800 Thousand USD | -11.11% |
| 1995 Q1 | 900 Thousand USD | 50.0% |
| 1994 Q2 | 700 Thousand USD | 16.67% |
| 1994 Q4 | 600 Thousand USD | -14.29% |
| 1994 FY | 2.6 Million USD | 18.18% |
| 1994 Q1 | 600 Thousand USD | -45.45% |
| 1994 Q3 | 700 Thousand USD | 0.0% |
| 1993 Q3 | 300 Thousand USD | -40.0% |
| 1993 Q4 | 1.1 Million USD | 266.67% |
| 1993 Q2 | 500 Thousand USD | -16.67% |
| 1993 Q1 | 600 Thousand USD | 50.0% |
| 1993 FY | 2.2 Million USD | 29.41% |
| 1992 Q3 | 400 Thousand USD | -20.0% |
| 1992 Q2 | 500 Thousand USD | 25.0% |
| 1992 FY | 1.7 Million USD | 88.89% |
| 1992 Q4 | 400 Thousand USD | 0.0% |
| 1992 Q1 | 400 Thousand USD | 33.33% |
| 1991 Q1 | - USD | -100.0% |
| 1991 FY | 900 Thousand USD | -52.63% |
| 1991 Q4 | 300 Thousand USD | 50.0% |
| 1991 Q3 | 200 Thousand USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1990 Q1 | 300 Thousand USD | -50.0% |
| 1990 FY | 1.9 Million USD | 46.15% |
| 1990 Q3 | - USD | -100.0% |
| 1990 Q4 | 1.5 Million USD | 0.0% |
| 1990 Q2 | 200 Thousand USD | -33.33% |
| 1989 Q1 | 700 Thousand USD | 0.0% |
| 1989 FY | 1.3 Million USD | 0.0% |
| 1989 Q3 | 400 Thousand USD | 500.0% |
| 1989 Q4 | 600 Thousand USD | 50.0% |
| 1989 Q2 | -100 Thousand USD | -114.29% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AbCellera Biologics Inc. | 38.02 Million USD | 88.438% |
| Alkermes plc | 1.37 Billion USD | 99.68% |
| Agenus Inc. | 139.61 Million USD | 96.851% |
| Aptorum Group Limited | -1.11 Million USD | 494.396% |
| Ardelyx, Inc. | 106.66 Million USD | 95.878% |
| Dyadic International, Inc. | 922.95 Thousand USD | -376.326% |
| Eton Pharmaceuticals, Inc. | 21.06 Million USD | 79.126% |
| Lantern Pharma Inc. | -174.84 Thousand USD | 2614.418% |
| Inhibikase Therapeutics, Inc. | -13.35 Million USD | 132.912% |
| Novavax, Inc. | 639.93 Million USD | 99.313% |
| Janux Therapeutics, Inc. | -46.83 Million USD | 109.386% |
| Pyxis Oncology, Inc. | -2 Million USD | 319.814% |
| TransCode Therapeutics, Inc. | -516.74 Thousand USD | 950.763% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 76.914% |
| Outlook Therapeutics, Inc. | -44.18 Thousand USD | 10049.045% |
| Madrigal Pharmaceuticals, Inc. | -527 Thousand USD | 934.209% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Syros Pharmaceuticals, Inc. | -98.21 Million USD | 104.476% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -448.165% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 5461.322% |
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 96.75% |
| Clearside Biomedical, Inc. | 7.87 Million USD | 44.146% |
| C4 Therapeutics, Inc. | -96.95 Million USD | 104.535% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.71% |
| AlloVir, Inc. | -398 Thousand USD | 1204.594% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 98.174% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -936.859% |
| Bicycle Therapeutics plc | -129.52 Million USD | 103.394% |
| BioXcel Therapeutics, Inc. | 120 Thousand USD | -3563.57% |
| ChromaDex Corporation | 50.78 Million USD | 91.342% |
| Chimerix, Inc. | 324 Thousand USD | -1256.878% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 114.105% |
| Caribou Biosciences, Inc. | -77.59 Million USD | 105.665% |
| CRISPR Therapeutics AG | 240.95 Million USD | 98.175% |
| Precision BioSciences, Inc. | 40.47 Million USD | 89.137% |
| Fate Therapeutics, Inc. | -98.16 Million USD | 104.479% |
| Fortress Biotech, Inc. | 57.85 Million USD | 92.401% |
| Fortress Biotech, Inc. | 57.85 Million USD | 92.401% |
| HOOKIPA Pharma Inc. | 16.57 Million USD | 73.48% |
| IDEAYA Biosciences, Inc. | -106.12 Million USD | 104.143% |
| Immix Biopharma, Inc. | -5468.00 USD | 80500.219% |
| Incyte Corporation | 3.44 Billion USD | 99.872% |
| Innoviva, Inc. | 261.06 Million USD | 98.316% |
| IO Biotech, Inc. | -756 Thousand USD | 681.519% |
| Jaguar Health, Inc. | 7.72 Million USD | 43.083% |
| Keros Therapeutics, Inc. | -664 Thousand USD | 762.091% |
| Ligand Pharmaceuticals Incorporated | 119.75 Million USD | 96.329% |
| ContextLogic Inc. | 59 Million USD | 92.549% |
| MiMedx Group, Inc. | 266.84 Million USD | 98.352% |
| MEI Pharma, Inc. | 49.32 Million USD | 91.087% |
| NextCure, Inc. | -3.68 Million USD | 219.335% |
| Onconetix, Inc. | -1.12 Million USD | 490.03% |
| Oncternal Therapeutics, Inc. | -28.96 Million USD | 115.176% |
| Opthea Limited | 21.72 Thousand USD | -20140.718% |
| Psyence Biomedical Ltd. | -240.00 USD | 1831885.0% |
| Vaxcyte, Inc. | -75 Million USD | 105.862% |
| PDS Biotechnology Corporation | -57.32 Thousand USD | 7768.918% |
| Precigen, Inc. | 106 Thousand USD | -4047.438% |
| Pharming Group N.V. | 220.1 Million USD | 98.003% |
| Phathom Pharmaceuticals, Inc. | 515 Thousand USD | -753.647% |
| Pieris Pharmaceuticals, Inc. | 1 Million USD | -335.707% |
| PureTech Health plc | -1.6 Million USD | 374.254% |
| Rigel Pharmaceuticals, Inc. | 109.77 Million USD | 95.995% |
| Avidity Biosciences, Inc. | -181.4 Million USD | 102.423% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 109.699% |
| Sol-Gel Technologies Ltd. | -21.98 Million USD | 119.995% |
| Acelyrin, Inc. | -115 Thousand USD | 3922.856% |
| Salarius Pharmaceuticals, Inc. | -10.05 Thousand USD | 43839.767% |
| Summit Therapeutics Inc. | -2.05 Million USD | 314.453% |
| Sensei Biotherapeutics, Inc. | -571 Thousand USD | 869.927% |
| Senti Biosciences, Inc. | -2.68 Million USD | 263.857% |
| Stoke Therapeutics, Inc. | 4.05 Million USD | -8.523% |
| Elevation Oncology, Inc. | -39 Thousand USD | 11372.523% |
| Alaunos Therapeutics, Inc. | -4.79 Million USD | 191.627% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 211.523% |
| Entrada Therapeutics, Inc. | 29.12 Million USD | 84.908% |
| VistaGen Therapeutics, Inc. | 496 Thousand USD | -786.348% |
| Kintara Therapeutics, Inc. | -55 Thousand USD | 8093.244% |
| Wave Life Sciences Ltd. | 104.09 Million USD | 95.777% |
| Seer, Inc. | 7.02 Million USD | 37.437% |
| Verrica Pharmaceuticals Inc. | 4.37 Million USD | -0.418% |
| Aadi Bioscience, Inc. | 21.54 Million USD | 79.595% |
| ESSA Pharma Inc. | -118.49 Thousand USD | 3810.226% |
| GlycoMimetics, Inc. | -143.3 Thousand USD | 3167.867% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Inhibrx Biosciences, Inc. | 609 Thousand USD | -621.886% |
| Akebia Therapeutics, Inc. | 120.47 Million USD | 96.351% |
| Catalyst Pharmaceuticals, Inc. | 313.67 Million USD | 98.598% |
| Longboard Pharmaceuticals, Inc. | -5000.00 USD | 88025.68% |
| Orchestra BioMed Holdings, Inc. | 2.57 Million USD | -70.796% |
| Alzamend Neuro, Inc. | -50.74 Thousand USD | 8764.336% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 85.04% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 1994.95% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 993.554% |
| Rocket Pharmaceuticals, Inc. | -7.09 Million USD | 161.937% |
| Aptose Biosciences Inc. | -474.54 Thousand USD | 1026.421% |
| ZyVersa Therapeutics, Inc. | -10.4 Thousand USD | 42371.962% |
| Soligenix, Inc. | 97.31 Thousand USD | -4417.767% |
| Century Therapeutics, Inc. | -10.8 Million USD | 140.672% |
| Kura Oncology, Inc. | -849 Thousand USD | 617.819% |
| TScan Therapeutics, Inc. | -67.1 Million USD | 106.551% |
| Intensity Therapeutics, Inc. | -147 Thousand USD | 3090.669% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 99.03 Million USD | 95.561% |
| Autolus Therapeutics plc | -4.86 Million USD | 190.328% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 41.38 Million USD | 89.377% |
| Eterna Therapeutics Inc. | -168 Thousand USD | 2716.836% |
| Adaptive Biotechnologies Corporation | 94.72 Million USD | 95.359% |
| GRI Bio, Inc. | 10.84 Million USD | 59.448% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | -73.083% |
| Tenaya Therapeutics, Inc. | -8.68 Million USD | 150.608% |
| IGM Biosciences, Inc. | -211.66 Million USD | 102.077% |
| INmune Bio, Inc. | 155 Thousand USD | -2736.312% |
| Heron Therapeutics, Inc. | 61.93 Million USD | 92.902% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 391.862% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 777.964% |
| Entero Therapeutics, Inc. | -29.27 Thousand USD | 15117.709% |
| Milestone Pharmaceuticals Inc. | 402 Thousand USD | -993.603% |
| X4 Pharmaceuticals, Inc. | -1.99 Million USD | 320.255% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 1504.564% |
| Coherus BioSciences, Inc. | 94.46 Million USD | 95.346% |
| Verastem, Inc. | -62 Thousand USD | 7190.781% |
| Abeona Therapeutics Inc. | 2.43 Million USD | -80.546% |
| Pliant Therapeutics, Inc. | -261 Thousand USD | 1784.4% |
| Tonix Pharmaceuticals Holding Corp. | 3.02 Million USD | -45.236% |
| Histogen Inc. | 3.76 Million USD | -16.643% |
| Aprea Therapeutics, Inc. | 576.17 Thousand USD | -663.007% |
| Surrozen, Inc. | -27.23 Million USD | 116.145% |
| Organovo Holdings, Inc. | -5.38 Million USD | 181.579% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | -1.2 Million USD | 464.873% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 117.142% |
| CASI Pharmaceuticals, Inc. | 20.05 Million USD | 78.076% |
| Cadrenal Therapeutics, Inc. Common Stock | -1980.00 USD | 222134.545% |
| Centessa Pharmaceuticals plc | 6.06 Million USD | 27.531% |
| Hepion Pharmaceuticals, Inc. | -67.13 Thousand USD | 6648.814% |
| Arcturus Therapeutics Holdings Inc. | 154.79 Million USD | 97.16% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -2915.284% |
| Apollomics, Inc. | 127 Thousand USD | -3361.641% |
| Amarin Corporation plc | 165.54 Million USD | 97.344% |
| Mesoblast Limited | -9.81 Million USD | 144.791% |
| Turnstone Biologics Corp. | 16.5 Million USD | 73.366% |
| Kymera Therapeutics, Inc. | -110.48 Million USD | 103.979% |
| Synaptogenix, Inc. | -6347.00 USD | 69365.543% |
| Tiziana Life Sciences Ltd | -51 Thousand USD | 8720.165% |
| Aurinia Pharmaceuticals Inc. | 161.36 Million USD | 97.276% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 1.75 Billion USD | 99.75% |
| Better Therapeutics, Inc. | -2.72 Million USD | 261.095% |
| Nurix Therapeutics, Inc. | -112.16 Million USD | 103.92% |
| Apellis Pharmaceuticals, Inc. | 338.08 Million USD | 98.7% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 38636.851% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | -6.26 Million USD | 170.228% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 496.777% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 7.31 Million USD | 39.925% |
| Insmed Incorporated | 239.63 Million USD | 98.165% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 3.57 Million USD | -22.87% |
| OmniAb, Inc. | 14.66 Million USD | 70.026% |
| Alector, Inc. | -95.05 Million USD | 104.625% |
| Seres Therapeutics, Inc. | 125.62 Million USD | 96.5% |
| Checkpoint Therapeutics, Inc. | -43.46 Million USD | 110.115% |
| Zai Lab Limited | 170.9 Million USD | 97.428% |
| Revance Therapeutics, Inc. | 81.87 Million USD | 94.631% |
| Aura Biosciences, Inc. | -1.29 Million USD | 439.481% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -3281.757% |
| Immunic, Inc. | -111 Thousand USD | 4060.616% |
| Tarsus Pharmaceuticals, Inc. | 15.85 Million USD | 72.27% |
| Veracyte, Inc. | 248.14 Million USD | 98.228% |
| InMed Pharmaceuticals Inc. | -6.98 Billion USD | 100.063% |
| FibroGen, Inc. | 128.9 Million USD | 96.589% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Adial Pharmaceuticals, Inc. | -564.00 USD | 779582.979% |
| Sonnet BioTherapeutics Holdings, Inc. | -11.66 Million USD | 137.682% |
| Jazz Pharmaceuticals plc | 3.39 Billion USD | 99.871% |
| Cyclacel Pharmaceuticals, Inc. | 389 Thousand USD | -1030.15% |
| Amylyx Pharmaceuticals, Inc. | 355.34 Million USD | 98.763% |
| TG Therapeutics, Inc. | 219.1 Million USD | 97.994% |
| Galecto, Inc. | -830 Thousand USD | 629.673% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 417.421% |
| Fortrea Holdings Inc. | 424 Million USD | 98.963% |
| KalVista Pharmaceuticals, Inc. | -86.16 Million USD | 105.102% |
| Aptevo Therapeutics Inc. | -567 Thousand USD | 875.359% |
| XBiotech Inc. | -1.74 Million USD | 352.081% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 496.777% |
| Lyra Therapeutics, Inc. | -46.47 Million USD | 109.46% |
| Foghorn Therapeutics Inc. | -75.53 Million USD | 105.82% |
| Y-mAbs Therapeutics, Inc. | 73.4 Million USD | 94.011% |
| Theravance Biopharma, Inc. | 16.8 Million USD | 73.836% |
| Ultragenyx Pharmaceutical Inc. | 389.04 Million USD | 98.87% |
| Metagenomi, Inc. Common Stock | -49.64 Million USD | 108.855% |
| Vaxxinity, Inc. | -2.23 Million USD | 296.79% |
| BioCryst Pharmaceuticals, Inc. | 326.75 Million USD | 98.655% |
| Gain Therapeutics, Inc. | -11.32 Million USD | 138.823% |
| Cartesian Therapeutics, Inc. | 24.45 Million USD | 82.02% |
| NexImmune, Inc. | -1.02 Million USD | 528.917% |
| Creative Medical Technology Holdings, Inc. | 5400.00 USD | -81312.667% |
| Marker Therapeutics, Inc. | -7.1 Million USD | 161.87% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.961% |
| Chemomab Therapeutics Ltd. | -66.82 Thousand USD | 6678.604% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | -3.55 Million USD | 223.804% |
| Ainos, Inc. | -253.73 Thousand USD | 1832.642% |
| Pluri Inc. | 322 Thousand USD | -1265.306% |
| Prothena Corporation plc | -129.2 Million USD | 103.403% |
| Adaptimmune Therapeutics plc | 50.42 Million USD | 91.281% |
| Celularity Inc. | 6.75 Million USD | 34.918% |
| Rallybio Corporation | -150 Thousand USD | 3030.856% |
| Cue Biopharma, Inc. | -32.6 Million USD | 113.483% |
| MeiraGTx Holdings plc | 287 Thousand USD | -1431.806% |
| Omeros Corporation | -69.77 Million USD | 106.3% |
| Humacyte, Inc. | -76.55 Million USD | 105.743% |
| Immunocore Holdings plc | 248.39 Million USD | 98.23% |
| Cocrystal Pharma, Inc. | -15.16 Million USD | 128.982% |
| Cidara Therapeutics, Inc. | 62.38 Million USD | 92.953% |
| Blueprint Medicines Corporation | 236.58 Million USD | 98.142% |
| CalciMedica, Inc. | -58 Thousand USD | 7679.8% |
| Cabaletta Bio, Inc. | -1.42 Million USD | 408.295% |
| Marinus Pharmaceuticals, Inc. | 29.05 Million USD | 84.869% |
| Scholar Rock Holding Corporation | -2.84 Million USD | 254.581% |
| Sana Biotechnology, Inc. | -30.86 Million USD | 114.244% |
| Pulmatrix, Inc. | -8.22 Million USD | 153.483% |
| Elicio Therapeutics, Inc. | -1.17 Million USD | 475.751% |
| Vigil Neuroscience, Inc. | -399 Thousand USD | 1201.826% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 101.102% |
| Adlai Nortye Ltd. American Depositary Shares | 2.77 Million USD | -58.391% |
| Cytokinetics, Incorporated | -322.59 Million USD | 101.363% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | -409.948% |
| Protara Therapeutics, Inc. | -341 Thousand USD | 1389.233% |
| Vor Biopharma Inc. | -3.49 Million USD | 225.896% |
| Roivant Sciences Ltd. | 109.23 Million USD | 95.975% |
| Evogene Ltd. | 1.39 Million USD | -214.245% |
| ProKidney Corp. | -3.16 Million USD | 238.728% |
| Applied Therapeutics, Inc. | -43.91 Million USD | 110.012% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 6.85 Million USD | 35.886% |
| CorMedix Inc. | -205.56 Thousand USD | 2238.666% |
| BioLineRx Ltd. | 1.1 Million USD | -296.777% |
| Tango Therapeutics, Inc. | -78.67 Million USD | 105.588% |
| Galectin Therapeutics Inc. | -33 Thousand USD | 13422.073% |
| Atai Life Sciences N.V. | -5000.00 USD | 88025.68% |
| Renovaro Biosciences Inc. | -121.85 Thousand USD | 3707.681% |
| Aerovate Therapeutics, Inc. | -96 Thousand USD | 4679.463% |
| Zentalis Pharmaceuticals, Inc. | -1.38 Million USD | 416.507% |
| Sagimet Biosciences Inc. | 2 Million USD | -119.814% |
| MediciNova, Inc. | 979.7 Thousand USD | -348.735% |
| Praxis Precision Medicines, Inc. | -84.31 Million USD | 105.214% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 4749.446% |
| GeoVax Labs, Inc. | -20.72 Million USD | 121.217% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 98.202% |
| Biomea Fusion, Inc. | -4.2 Million USD | 204.649% |
| PTC Therapeutics, Inc. | 872.33 Million USD | 99.496% |
| Mereo BioPharma Group plc | 7.42 Million USD | 40.799% |
| Cullinan Oncology, Inc. | -310 Thousand USD | 1518.156% |
| Syndax Pharmaceuticals, Inc. | -12 Thousand USD | 36735.7% |
| Absci Corporation | -41.84 Million USD | 110.505% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 88025.68% |
| 4D Molecular Therapeutics, Inc. | -76.37 Million USD | 105.756% |
| Dyne Therapeutics, Inc. | -2.46 Million USD | 278.638% |
| Kiniksa Pharmaceuticals, Ltd. | 213.73 Million USD | 97.943% |
| Ventyx Biosciences, Inc. | -941 Thousand USD | 567.193% |
| Allakos Inc. | -6.14 Million USD | 171.589% |
| Imunon, Inc. | -720 Thousand USD | 710.591% |
| Fulcrum Therapeutics, Inc. | -68.99 Million USD | 106.372% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 99.076% |
| BioAtla, Inc. | -103.73 Million USD | 104.238% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 38636.851% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 2569.822% |
| Allogene Therapeutics, Inc. | -242.81 Million USD | 101.811% |
| Larimar Therapeutics, Inc. | -311 Thousand USD | 1513.596% |
| XOMA Corporation | 3.86 Million USD | -13.864% |
| Kezar Life Sciences, Inc. | -70.08 Million USD | 106.273% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 70.283% |
| aTyr Pharma, Inc. | -2.38 Million USD | 284.099% |
| Aligos Therapeutics, Inc. | 12.46 Million USD | 64.717% |
| Akero Therapeutics, Inc. | -29 Thousand USD | 15259.6% |
| Viridian Therapeutics, Inc. | -1 Million USD | 536.139% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 13.00 USD | -33817469.231% |
| Akari Therapeutics, Plc | -4000.00 USD | 110007.1% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 99.31% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -2157.886% |
| UroGen Pharma Ltd. | 73.35 Million USD | 94.007% |
| Sutro Biopharma, Inc. | -26.69 Million USD | 116.469% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -37766.357% |
| Orgenesis Inc. | -5.72 Million USD | 176.791% |
| Entera Bio Ltd. | -56 Thousand USD | 7950.507% |
| GH Research PLC | -315 Thousand USD | 1495.646% |
| Lisata Therapeutics, Inc. | -189 Thousand USD | 2426.076% |
| Reneo Pharmaceuticals, Inc. | -525 Thousand USD | 937.387% |
| Xencor, Inc. | -85.26 Million USD | 105.156% |
| 60 Degrees Pharmaceuticals, Inc. | -220.97 Thousand USD | 2089.476% |
| Replimune Group, Inc. | -2.65 Million USD | 265.585% |
| Coeptis Therapeutics Holdings, Inc. | -1 Million USD | 539.086% |
| Vanda Pharmaceuticals Inc. | 177.84 Million USD | 97.528% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -2157.886% |
| Portage Biotech Inc. | -54 Thousand USD | 8241.267% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 4749.446% |
| Olema Pharmaceuticals, Inc. | -377 Thousand USD | 1266.123% |
| OncoCyte Corporation | 413 Thousand USD | -964.476% |
| Qualigen Therapeutics, Inc. | -4495.00 USD | 97903.871% |
| Processa Pharmaceuticals, Inc. | -222.00 USD | 1980408.108% |
| Purple Biotech Ltd. | -196 Thousand USD | 2343.002% |
| CollPlant Biotechnologies Ltd. | 8.96 Million USD | 50.978% |
| scPharmaceuticals Inc. | 9.78 Million USD | 55.057% |
| ProMIS Neurosciences, Inc. | -10.44 Million USD | 142.09% |
| HilleVax, Inc. | -2.15 Million USD | 303.909% |
| NeuroSense Therapeutics Ltd. | -97 Thousand USD | 4632.252% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | -15 Thousand USD | 29400.746% |
| Neumora Therapeutics, Inc. Common Stock | -668 Thousand USD | 758.126% |
| Atossa Therapeutics, Inc. | -23 Thousand USD | 19214.278% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | -7506.16 USD | 58669.015% |
| Savara Inc. | -44.26 Million USD | 109.932% |
| Curis, Inc. | 9.81 Million USD | 55.19% |
| Daré Bioscience, Inc. | 2.76 Million USD | -58.738% |
| Carmell Therapeutics Corporation | -124.78 Thousand USD | 3623.002% |
| Titan Pharmaceuticals, Inc. | -1.72 Million USD | 354.267% |
| Achieve Life Sciences, Inc. | -228 Thousand USD | 2028.195% |
| BeiGene, Ltd. | 2.07 Billion USD | 99.789% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 257.24% |
| Revolution Medicines, Inc. Warrant | -399.66 Million USD | 101.1% |
| Protagonist Therapeutics, Inc. | 56.68 Million USD | 92.245% |
| Erasca, Inc. | -3.73 Million USD | 217.8% |
| bluebird bio, Inc. | -4.03 Million USD | 209.089% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 15679.715% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.769% |
| DBV Technologies S.A. | 15.72 Million USD | 72.048% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 15679.715% |
| Moderna, Inc. | 2.15 Billion USD | 99.796% |
| Vincerx Pharma, Inc. | -915 Thousand USD | 580.468% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 45.088% |
| Molecular Templates, Inc. | 50.39 Million USD | 91.276% |
| Acrivon Therapeutics, Inc. Common Stock | -536 Thousand USD | 920.202% |
| Travere Therapeutics, Inc. | 133.78 Million USD | 96.714% |
| Monte Rosa Therapeutics, Inc. | -6.22 Million USD | 170.657% |
| Spruce Biosciences, Inc. | -39.34 Million USD | 111.174% |
| Celldex Therapeutics, Inc. | -111.12 Million USD | 103.956% |
| Cogent Biosciences, Inc. | -3.58 Million USD | 222.527% |
| MacroGenics, Inc. | 50.52 Million USD | 91.299% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | -6.09 Million USD | 172.094% |
| Prime Medicine, Inc. | -147.9 Million USD | 102.972% |
| Aditxt, Inc. | -111.66 Thousand USD | 4037.206% |
| Adagene Inc. | 18.11 Million USD | 75.727% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 488 Thousand USD | -800.878% |
| Maravai LifeSciences Holdings, Inc. | 140.2 Million USD | 96.864% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 157.83 Million USD | 97.215% |
| SciSparc Ltd. | 2.19 Million USD | -100.195% |
| Vericel Corporation | 135.57 Million USD | 96.757% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 17650.737% |
| Minerva Neurosciences, Inc. | -30.98 Thousand USD | 14289.801% |
| Generation Bio Co. | -73.91 Million USD | 105.948% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | -437 Thousand USD | 1106.015% |
| Arcutis Biotherapeutics, Inc. | 54.61 Million USD | 91.951% |
| Invivyd, Inc. | -2.02 Million USD | 316.779% |
| Relay Therapeutics, Inc. | -300.84 Million USD | 101.461% |
| Quoin Pharmaceuticals, Ltd. | -103.43 Thousand USD | 4350.163% |
| Spero Therapeutics, Inc. | 96.36 Million USD | 95.438% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 98.28 Million USD | 95.527% |
| ADMA Biologics, Inc. | 88.21 Million USD | 95.017% |
| Clene Inc. | 533 Thousand USD | -724.819% |
| Capricor Therapeutics, Inc. | 24.1 Million USD | 81.765% |
| Boundless Bio, Inc. Common Stock | -957 Thousand USD | 559.382% |
| GeoVax Labs, Inc. | -20.72 Million USD | 121.217% |
| Recursion Pharmaceuticals, Inc. | 1.98 Million USD | -121.141% |
| Citius Pharmaceuticals, Inc. | -194.31 Thousand USD | 2362.441% |
| Contineum Therapeutics, Inc. Class A Common Stock | 49.8 Million USD | 91.173% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 161.989% |
| ALX Oncology Holdings Inc. | -836 Thousand USD | 625.871% |
| Vir Biotechnology, Inc. | 83.41 Million USD | 94.73% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -5913.081% |
| Ocular Therapeutix, Inc. | 53.16 Million USD | 91.73% |
| Verve Therapeutics, Inc. | -173.18 Million USD | 102.538% |
| Trevena, Inc. | 1.45 Million USD | -202.15% |
| Surrozen, Inc. | -27.23 Million USD | 116.145% |
| Tyra Biosciences, Inc. | -353 Thousand USD | 1345.406% |
| Cingulate Inc. | -582.91 Thousand USD | 854.186% |
| Galmed Pharmaceuticals Ltd. | -31 Thousand USD | 14281.561% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 122.317% |
| Tenax Therapeutics, Inc. | -7570.00 USD | 58175.086% |
| Terns Pharmaceuticals, Inc. | -881 Thousand USD | 599.011% |
| ACADIA Pharmaceuticals Inc. | 680.7 Million USD | 99.354% |
| Connect Biopharma Holdings Limited | -988 Thousand USD | 544.968% |
| Clearmind Medicine Inc. | -56.34 Thousand USD | 7902.854% |
| Kronos Bio, Inc. | 1.37 Million USD | -220.429% |
| Bolt Biotherapeutics, Inc. | -53.66 Million USD | 108.192% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 1605.577% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 1000.299% |
| ImmunityBio, Inc. | -17.89 Million USD | 124.574% |
| Korro Bio, Inc. | -3.63 Million USD | 221.11% |
| Kineta, Inc. | 5.43 Million USD | 19.082% |
| BioVie Inc. | -229.37 Thousand USD | 2016.619% |
| Codexis, Inc. | 57.33 Million USD | 92.332% |
| Celularity Inc. | 6.75 Million USD | 34.918% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | -9.551% |
| Celcuity Inc. | -142.77 Thousand USD | 3179.234% |
| Virax Biolabs Group Limited | 50.59 Thousand USD | -8590.026% |
| Cibus, Inc. | 1.42 Million USD | -209.162% |
| Eledon Pharmaceuticals, Inc. | -374 Thousand USD | 1275.477% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 119.182% |
| IN8bio, Inc. | -2.5 Million USD | 275.781% |
| Kodiak Sciences Inc. | -25.94 Million USD | 116.943% |
| Annexon, Inc. | -3.26 Million USD | 234.566% |
| Adverum Biotechnologies, Inc. | -2.04 Million USD | 315.082% |
| Assembly Biosciences, Inc. | -41.73 Million USD | 110.533% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -586.919% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 99.435% |
| Eyenovia, Inc. | - USD | -Infinity% |
| Puma Biotechnology, Inc. | 172.95 Million USD | 97.458% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | -1.9 Million USD | 331.383% |
| Arcellx, Inc. | 108.27 Million USD | 95.94% |
| Cardiff Oncology, Inc. | -32.36 Million USD | 113.582% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 94.449% |
| Regulus Therapeutics Inc. | -21.15 Million USD | 120.784% |
| Moolec Science SA | -143.3 Thousand USD | 3167.781% |
| Acumen Pharmaceuticals, Inc. | -42.31 Million USD | 110.389% |
| Geron Corporation | -123.5 Million USD | 103.56% |
| LAVA Therapeutics N.V. | 3.28 Million USD | -33.748% |
| Royalty Pharma plc | 1.79 Billion USD | 99.755% |
| Atea Pharmaceuticals, Inc. | -70.09 Million USD | 106.272% |
| Greenwich LifeSciences, Inc. | -3612.00 USD | 121813.289% |
| TFF Pharmaceuticals, Inc. | 231.39 Thousand USD | -1799.937% |
| Mersana Therapeutics, Inc. | -111.41 Million USD | 103.946% |
| Humacyte, Inc. | -76.55 Million USD | 105.743% |
| Structure Therapeutics Inc. | -949.17 Thousand USD | 563.169% |
| 89bio, Inc. | -273 Thousand USD | 1710.36% |
| PMV Pharmaceuticals, Inc. | -1.25 Million USD | 449.744% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | -848 Thousand USD | 618.43% |
| Trevi Therapeutics, Inc. | -123 Thousand USD | 3674.215% |
| Lexicon Pharmaceuticals, Inc. | 1.11 Million USD | -292.876% |
| Notable Labs, Ltd. | 113 Thousand USD | -3790.517% |
| Liquidia Corporation | 14.6 Million USD | 69.888% |
| Mustang Bio, Inc. | -2.22 Million USD | 297.586% |
| Immunovant, Inc. | -231 Thousand USD | 2003.153% |
| Quantum-Si incorporated | 488 Thousand USD | -800.878% |
| Arbutus Biopharma Corporation | -55.55 Million USD | 107.913% |
| DiaMedica Therapeutics Inc. | -30 Thousand USD | 14754.28% |
| Vera Therapeutics, Inc. | 1.86 Million USD | -136.105% |
| Acasti Pharma Inc. | -11 Thousand USD | 40066.218% |
| MiNK Therapeutics, Inc. | -204.61 Thousand USD | 2248.543% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 777.964% |
| Xenon Pharmaceuticals Inc. | -167.51 Million USD | 102.624% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -287.481% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Tempest Therapeutics, Inc. | -381 Thousand USD | 1253.88% |
| Soleno Therapeutics, Inc. | -1.95 Million USD | 324.529% |
| PepGen Inc. | -1.18 Million USD | 471.308% |
| Moleculin Biotech, Inc. | -127 Thousand USD | 3561.641% |
| United Therapeutics Corporation | 2.07 Billion USD | 99.788% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 119.2% |
| Solid Biosciences Inc. | -76.56 Million USD | 105.742% |
| BriaCell Therapeutics Corp. | -82.58 Thousand USD | 5423.473% |
| Immuneering Corporation | -764.13 Thousand USD | 675.326% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 66.26 Thousand USD | -6534.498% |
| Belite Bio, Inc | -399 Thousand USD | 1201.826% |
| XOMA Corporation | 3.86 Million USD | -13.864% |
| ARS Pharmaceuticals, Inc. | -20.03 Million USD | 121.942% |
| Bionomics Limited | -434.44 Thousand USD | 1111.922% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 509.337% |
| uniQure N.V. | 2.21 Million USD | -98.478% |
| Cassava Sciences, Inc. | -89.42 Million USD | 104.916% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | -92.06 Million USD | 104.775% |
| Forte Biosciences, Inc. | -9000.00 USD | 48947.6% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | -835 Thousand USD | 626.501% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | -437 Thousand USD | 1106.015% |
| Altimmune, Inc. | -65.37 Million USD | 106.725% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 98.786% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 509.337% |
| Compugen Ltd. | 31.45 Million USD | 86.024% |
| Peak Bio, Inc. | 367.76 Thousand USD | -1095.393% |
| Zevra Therapeutics, Inc. | 24.51 Million USD | 82.068% |
| Benitec Biopharma Inc. | 108 Thousand USD | -3970.633% |
| Spyre Therapeutics, Inc. | -78 Thousand USD | 5736.262% |
| NKGen Biotech, Inc. Common Stock | -1.2 Million USD | 465.443% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | -1.82 Million USD | 341.289% |
| Aileron Therapeutics, Inc. | -119 Thousand USD | 3794.356% |
| NKGen Biotech, Inc. Warrants | -1.2 Million USD | 465.443% |
| Instil Bio, Inc. | -4.75 Million USD | 192.437% |
| argenx SE | 1.1 Billion USD | 99.603% |
| Immunome, Inc. | -8.9 Million USD | 149.358% |
| Compass Therapeutics, Inc. | -1.89 Million USD | 332.608% |
| Verona Pharma plc | -679.62 Thousand USD | 746.87% |
| enGene Holdings Inc. Warrants | -175 Thousand USD | 2612.162% |
| Shattuck Labs, Inc. | -2.38 Million USD | 284.331% |
| CervoMed Inc. | -1.29 Million USD | 439.842% |
| LENZ Therapeutics, Inc. | -2.4 Million USD | 282.646% |
| Plus Therapeutics, Inc. | -4.77 Million USD | 192.03% |
| Dianthus Therapeutics, Inc. | 2.47 Million USD | -77.915% |
| Moolec Science SA | -143.3 Thousand USD | 3167.781% |
| Enveric Biosciences, Inc. | -408.03 Thousand USD | 1177.441% |
| Inovio Pharmaceuticals, Inc. | -2.67 Million USD | 264.561% |
| AnaptysBio, Inc. | 14.78 Million USD | 70.257% |
| Design Therapeutics, Inc. | -537 Thousand USD | 918.675% |
| Leap Therapeutics, Inc. | -427 Thousand USD | 1129.575% |
| NeurAxis, Inc. | 2.15 Million USD | -103.843% |
| Seelos Therapeutics, Inc. | 2.14 Million USD | -104.859% |
| Lumos Pharma, Inc. | 2 Million USD | -119.048% |
| Achilles Therapeutics plc | -4.73 Million USD | 192.92% |
| enGene Holdings Inc. Common Stock | -175 Thousand USD | 2612.162% |
| 180 Life Sciences Corp. | -105.67 Thousand USD | 4260.193% |
| Opiant Pharmaceuticals, Inc. | 31.65 Million USD | 86.114% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | -409.948% |
| ORIC Pharmaceuticals, Inc. | -1.03 Million USD | 525.997% |
| CG Oncology, Inc. Common stock | -45.54 Million USD | 109.652% |
| Fractyl Health, Inc. Common Stock | 43 Thousand USD | -10123.916% |
| Rani Therapeutics Holdings, Inc. | -822 Thousand USD | 634.828% |
| MoonLake Immunotherapeutics | -13.15 Thousand USD | 33511.491% |
| Palisade Bio, Inc. | 246 Thousand USD | -1687.107% |
| Tourmaline Bio, Inc. | -33 Thousand USD | 13422.073% |
| Beam Therapeutics Inc. | -59.67 Million USD | 107.367% |
| Neurogene Inc. | -3.26 Million USD | 234.773% |
| Mirum Pharmaceuticals, Inc. | 139.33 Million USD | 96.845% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | -3.69 Million USD | 219.076% |
| Sesen Bio, Inc. | 40 Million USD | 89.009% |
| Enliven Therapeutics, Inc. | -297 Thousand USD | 1580.23% |
| Kiora Pharmaceuticals, Inc. | -4.02 Million USD | 209.169% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 145.957% |
| Taysha Gene Therapies, Inc. | 14.08 Million USD | 68.776% |
| Athira Pharma, Inc. | -969 Thousand USD | 553.693% |
| Vaccinex, Inc. | -16 Million USD | 127.47% |
| HCW Biologics Inc. | -574.82 Thousand USD | 864.805% |
| XOMA Corporation | 3.86 Million USD | -13.864% |
| Nektar Therapeutics | 53.47 Million USD | 91.779% |
| Arvinas, Inc. | 71.8 Million USD | 93.877% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | -83.46 Million USD | 105.267% |
| Omega Therapeutics, Inc. | -62.77 Million USD | 107.003% |
| Quince Therapeutics, Inc. | -322 Thousand USD | 1465.306% |
| Rezolute, Inc. | -36 Thousand USD | 12311.9% |
| Clene Inc. | 533 Thousand USD | -724.819% |
| Indaptus Therapeutics, Inc. | -1284.00 USD | 342489.72% |
| BeyondSpring Inc. | 1.75 Million USD | -151.073% |
| Synlogic, Inc. | -1.92 Million USD | 328.497% |
| Allarity Therapeutics, Inc. | -37 Thousand USD | 11981.849% |
| Phio Pharmaceuticals Corp. | -6.33 Million USD | 169.43% |
| Peak Bio, Inc. | 367.76 Thousand USD | -1095.393% |
| Werewolf Therapeutics, Inc. | -18.96 Million USD | 123.183% |
| Krystal Biotech, Inc. | 47.6 Million USD | 90.765% |
| Karyopharm Therapeutics Inc. | 141.09 Million USD | 96.884% |
| SpringWorks Therapeutics, Inc. | 5.02 Million USD | 12.512% |
| Lipella Pharmaceuticals Inc. | -2.58 Million USD | 269.792% |
| MannKind Corporation | 136.19 Million USD | 96.772% |
| Ikena Oncology, Inc. | -50.49 Million USD | 108.707% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 108.81 Million USD | 95.96% |
| Gossamer Bio, Inc. | -4.38 Million USD | 200.257% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | -252 Thousand USD | 1844.557% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 88025.68% |
| Legend Biotech Corporation | 140.92 Million USD | 96.88% |
| Mural Oncology plc | -2.56 Million USD | 271.262% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 897.874% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | -100 Thousand USD | 4496.284% |
| Champions Oncology, Inc. | 20.75 Million USD | 78.817% |
| REGENXBIO Inc. | 53.02 Million USD | 91.71% |
| Ensysce Biosciences, Inc. | -5.35 Million USD | 182.067% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | -192.37 Thousand USD | 2385.268% |
| Edgewise Therapeutics, Inc. | -1.73 Million USD | 353.827% |
| Vaxart, Inc. | -60.76 Million USD | 107.235% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -262.78 Thousand USD | 1772.99% |
| Cellectis S.A. | 18 Thousand USD | -24323.8% |
| Longeveron Inc. | 221 Thousand USD | -1889.269% |
| Repare Therapeutics Inc. | -80.07 Million USD | 105.491% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.598% |
| Inozyme Pharma, Inc. | -1.29 Million USD | 439.744% |
| Revolution Medicines, Inc. | -399.66 Million USD | 101.1% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | -35 Thousand USD | 12660.811% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 49 Thousand USD | -8872.008% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.949% |
| Denali Therapeutics Inc. | -93.34 Million USD | 104.71% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 17650.737% |
| Veru Inc. | 7.56 Million USD | 41.894% |
| Corvus Pharmaceuticals, Inc. | -151 Thousand USD | 3011.446% |
| Cingulate Inc. | -582.91 Thousand USD | 854.186% |
| Passage Bio, Inc. | -3.72 Million USD | 218.148% |
| Context Therapeutics Inc. | -12.04 Thousand USD | 36601.86% |
| Exicure, Inc. | -1.42 Million USD | 408.945% |
| Day One Biopharmaceuticals, Inc. | -383 Thousand USD | 1247.855% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | -62.645% |
| Scinai Immunotherapeutics Ltd. | -512.67 Thousand USD | 957.519% |
| Rhythm Pharmaceuticals, Inc. | 68.12 Million USD | 93.547% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | -149.6 Thousand USD | 3038.555% |
| Carisma Therapeutics, Inc. | -59.2 Million USD | 107.425% |
| Unicycive Therapeutics, Inc. | 391 Thousand USD | -1024.369% |
| OmniAb, Inc. | 14.66 Million USD | 70.026% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 19.99 Million USD | 78.011% |
| Lipocine Inc. | -2.85 Million USD | 254.211% |
| Lexeo Therapeutics, Inc. Common Stock | -1.84 Million USD | 338.54% |
| Nautilus Biotechnology, Inc. | -5.7 Million USD | 177.06% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 391.862% |
| G1 Therapeutics, Inc. | 75.31 Million USD | 94.163% |
| Bellerophon Therapeutics, Inc. | -65 Thousand USD | 6863.514% |
| Sage Therapeutics, Inc. | 84.29 Million USD | 94.785% |
| Ocugen, Inc. | -33.53 Million USD | 113.109% |
| Mind Medicine (MindMed) Inc. | -3.16 Million USD | 239.035% |
| Q32 Bio Inc. | 578 Thousand USD | -660.603% |
| Brainstorm Cell Therapeutics Inc. | -265 Thousand USD | 1758.975% |
| Alumis Inc. Common Stock | -1.28 Million USD | 442.39% |
| Equillium, Inc. | 35.95 Million USD | 87.774% |
| Kyverna Therapeutics, Inc. | -1.7 Million USD | 357.544% |
| Coya Therapeutics, Inc. | 500.67 Thousand USD | -778.064% |
| CNS Pharmaceuticals, Inc. | -4134.00 USD | 106444.557% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 1797.407% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | -940.019% |
| Dominari Holdings Inc. | 2.03 Million USD | -115.61% |
| Edesa Biotech, Inc. | -183.47 Thousand USD | 2496.174% |
| vTv Therapeutics Inc. | -13.59 Million USD | 132.338% |
| Bio-Techne Corporation | 773.07 Million USD | 99.431% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 74.616% |
| Harmony Biosciences Holdings, Inc. | 460.78 Million USD | 99.046% |
| Prelude Therapeutics Incorporated | -1.16 Million USD | 476.072% |
| Candel Therapeutics, Inc. | -23.98 Million USD | 118.333% |
| iTeos Therapeutics, Inc. | 11.69 Million USD | 62.415% |
| Nkarta, Inc. | -5.86 Million USD | 174.907% |
| BioCardia, Inc. | -7.24 Million USD | 160.647% |
| Iterum Therapeutics plc | -1.75 Million USD | 351.216% |